Source-backed half-life profile
Morphine half-life calculator
Morphine is familiar enough to look simple, but metabolite and renal-context questions quickly complicate a parent-drug curve.
Every curve begins at 100%. No dose or measured body concentration is assumed.
X-axis: elapsed time. Y-axis: modeled percentage of the relative starting point remaining. This is a mathematical visualization, not a personal concentration estimate.
What a careful reader should notice first
The page works as an elimination-speed comparison, not as an analgesia or respiratory-risk model.
Source angle
Labels and pharmacology sources should be read for parent compound, metabolites, route, and patient population.
Do not use it for
Do not use the curve for dose conversion, pain control, impairment, or overdose-risk decisions.
Best next step
Compare with hydromorphone, oxycodone, and codeine, then read active-metabolite context.
Morphine: evidence and interpretation notes
Two hours belongs to an IV parent-drug context
Morphine labeling reports an effective terminal half-life of approximately two hours after intravenous administration. HalfLifeDB uses that value and labels the modeled context directly. It should not be confused with the apparent terminal profile of an extended-release product, which can be much longer because absorption and formulation continue to shape the concentration-time curve.
The parent drug is only one part of morphine pharmacokinetics. Much of a morphine exposure is excreted as the glucuronide metabolites M3G and M6G, which are cleared through the kidneys and can follow timelines different from the two-hour parent line.
| Evidence source | What it contributes | Important limit |
|---|---|---|
| Immediate-release solution labeling | Parent-drug, metabolism, and excretion context | Oral solution does not make the IV half-life a universal oral formulation value |
| Extended-release labeling | Shows an apparent terminal profile around 11 to 13 hours for that formulation | Absorption-controlled behavior should not replace the IV parent estimate |
| Lötsch systematic review | Fifty-seven studies and 1,232 patients examining metabolite ratios | Ratios varied widely across routes, populations, and methods |
| PubChem identity record | Compound identity | It does not establish formulation-specific kinetics |
Route and renal function change what remains
The systematic review found wide variation in metabolite-to-morphine ratios and higher ratios with renal impairment. Routes that avoided first-pass metabolism generally produced lower metabolite ratios than oral, buccal, or sublingual routes. This means two exposures with the same parent compound can leave different relative contributions from M3G and M6G.
The simple chart cannot model those parallel pathways. It also cannot infer kidney function or convert an extended-release product into an intravenous-equivalent line. Those would be clinical modeling tasks, not public educational calculations.
A short parent curve is not a risk clock
The two-hour line is useful for seeing how rapidly the selected IV parent profile declines compared with longer opioid entries. It is not an analgesia-duration, respiratory-risk, impairment, dose-conversion, or overdose model. Metabolites, formulation, route, health status, and repeated exposure all prevent that interpretation.
Morphine’s main lesson is therefore structural: always ask whether a quoted half-life belongs to the parent drug, a metabolite, or the delivery system before comparing it with another number.
Reading this curve
HalfLifeDB uses 2 h as a representative input for Morphine after IV administration. In the simplified model, about 0.0% remains after 24 hours and about 3% remains after five half-lives, or roughly 10 h.
This is a short curve. The modeled amount changes noticeably over the same day, while effects, metabolites, and safety questions can still follow a different timeline. The curve is relative: it does not estimate a person's measured concentration, effects, impairment, or time to clearance.
opioid context
Opioid pharmacokinetics can differ between parent compounds and metabolites, and timing can vary by route, formulation, and individual clearance.
- Half-life is not a measure of respiratory risk or functional impairment.
- Active metabolites can matter even when the parent compound declines.
- Extended-release products require separate source context.
Morphine timeline checkpoints
| Elapsed time | Modeled remaining | Reading note |
|---|---|---|
| 6 h | 12.5% | Long-tail portion of the model |
| 12 h | 1.56% | Low modeled remainder, not a clearance guarantee |
| 24 h | 0.02% | Low modeled remainder, not a clearance guarantee |
| 2.0 days | 0.00% | Low modeled remainder, not a clearance guarantee |
| 3.0 days | 0.00% | Low modeled remainder, not a clearance guarantee |
Nearby profiles by half-life
These entries sit near Morphine within the opioid group when sorted by representative half-life. That makes them curve comparisons, not statements about equal potency, effects, or risk.
- Oxycodone (3.5 h)
Pharmacokinetics at a glance
| Representative half-life | 2 h |
|---|---|
| Modeled analyte or phase | Morphine after IV administration |
| Curve type | Normalized, first-order decline |
Selection note: Product labeling reports an effective terminal half-life of about 2 hours after IV administration; extended-release formulations have longer apparent terminal values.
Sources and evidence context
A linked record is not automatically proof of the displayed value. Study, labeling, review, and compound identity sources serve different purposes; notes below identify limitations when they are known.
- Official labeling DailyMed label: Morphine sulfate solution.Official immediate-release solution labeling used for parent-drug and metabolite context.
- Official labeling DailyMed label: Morphine sulfate extended-release tablet.Official extended-release labeling illustrating how formulation changes the apparent terminal profile.
- Research abstract Lötsch J et al. Systematic review of factors affecting morphine and metabolite ratios (1998).Systematic review of 57 studies and 1,232 patients examining route, renal function, age, and metabolite ratios.
- Identity record PubChem Compound Summary: Morphine.Compound identity record; background only.
What this page does not answer
- It does not estimate impairment, intoxication, or fitness to drive.
- It does not predict urine, blood, saliva, or hair test results.
- It does not model repeated exposure, tolerance, withdrawal, or interactions.
- It does not replace clinician, pharmacist, toxicologist, or emergency guidance.
Continue with context
- All substance profiles
- Browse the opioid group
- Compare this curve
- Clearance and volume of distribution
- Bioavailability, route, and formulation
- Active metabolites and parent compounds
- First-order vs nonlinear kinetics
- Detection windows vs half-life
- Reading labels and source quality
Read the medical disclaimer, methodology, and profile review log before using the model for comparison.